secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001854270-23-000062
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio reports Q1 net loss $18.7M; cash $76.1M; SENTI-202 IND on track for 2H 2023
--------------------------------------------------------------------------------

- Net loss of $18.7M ($0.42 per share) vs $11.8M loss in Q1 2022; revenue $1.3M.
- Cash, equivalents & short-term investments $76.1M; cash runway expected through at least Q1 2024.
- R&D expense $11.3M (+49% YoY) from increased headcount for preclinical programs.
- SENTI-202 logic-gated CAR-NK on track for IND filing in 2H 2023; new AACR data shown.
- Technology transfer to Alameda cGMP facility started to support clinical-scale manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427023000062/0001854270-23-000062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427023000062/snti-20230509.htm
  HTML page:      https://secwatch.observer/filing/0001854270-23-000062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer